Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus
NCT ID: NCT06715189
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
80 participants
OBSERVATIONAL
2024-12-01
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MASLD patients with hepatic fibrosis
MASLD with hepatic fibrosis with type 2 diabetes mellitus
serum Adiponectine and Resistin
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
fibroscan
hepatic fibrosis detection in type 2 diabetes mellutis
MASLD without hepatic fibrosis
MASLD with out hepatic fibrosis with type 2 diabetes mellutis
serum Adiponectine and Resistin
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
fibroscan
hepatic fibrosis detection in type 2 diabetes mellutis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum Adiponectine and Resistin
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
fibroscan
hepatic fibrosis detection in type 2 diabetes mellutis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elzahraa Kadry Mohamed
Teaching assistant fellow At sohag teaching hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
usama M Abdelaal, professor
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. J Hepatol. 2024 Feb;80(2):178-180. doi: 10.1016/j.jhep.2023.10.011. Epub 2023 Nov 30. No abstract available.
Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-24-11--5MD
Identifier Type: -
Identifier Source: org_study_id